Use of Tetracyclines During the Different Stages of Pregnancy
John N. van den Anker
DOI: https://doi.org/10.1001/jamanetworkopen.2024.47322
2024-11-22
JAMA Network Open
Abstract:Nakitanda and colleagues 1 report their findings of a large population-based cohort study investigating the risk of developing major congenital malformations after exposure to tetracyclines during the first trimester of pregnancy. They conclude that exposure to tetracyclines during the first trimester is not associated with an increased risk of developing major congenital malformations. However, the authors indicate that additional investigations are still necessary to rule out potential risks because of power limitations for several major congenital malformation subgroups and individual malformations. It is important to realize that their study 1 is considerably larger (almost 4-fold) than earlier reports in terms of the number of exposed infants (6340 vs 1694 infants in Cooper et al 2 ) and documented cases, and also covered a broad range of major congenital malformation subgroups, as well as individual major congenital malformations. Despite all these great improvements in their population-based study, it is still impossible to reach a definitive conclusion regarding the safety of tetracyclines during pregnancy. Bevelander et al 3 reported 65 years ago that tetracyclines administered during pregnancy pass through the placenta, are concentrated in the fetal skeleton, and may diminish skeletal growth. On the basis of these and subsequent additional findings, tetracyclines have been labeled as potentially harmful because of the ability to cause developmental malformations in the fetus, lifelong caramel discoloration of the teeth after exposure prenatally or during the first 8 years of life, and, once in a while, lethal drug-induced liver toxicity described in pregnant individuals. 4 However, we need to realize that doxycycline is currently the most frequently used tetracycline during pregnancy. 5 It was developed after tetracyclines as a class of drugs already had been labeled as potentially harmful. Doxycycline is prescribed to cure a myriad of infections, such as malaria, sexually transmitted diseases (eg, chlamydia and syphilis), dermatitis and acne, and rickettsial illnesses, including Lyme disease, which is caused by the bite of ticks, mites, flees or lice. In addition, it is effective against tularemia, cholera, and bubonic plague, which might be used during bacteriological warfare. 4 ,6 A few years ago, Cross and colleagues 4 provided several arguments, based on their systematic review, that doxycycline might not be associated with the same adverse events as the other tetracyclines. In other words, the jury is still out on the safety of the use of doxycycline during pregnancy. Its use might be less or even not harmful at all compared with the use of the older tetracyclines. This lack of necessary knowledge for optimal use of doxycycline or any of the other tetracyclines during pregnancy all boils down to the fact that pregnant persons still need to be viewed as therapeutic orphans. Pregnant individuals (and those of child-bearing potential) have historically been excluded from clinical trials because of the well-intentioned attempt to protect the vulnerable fetus. Unfortunately, an unintended consequence of this protection has been an information gap that makes prescribing drugs for pregnant individuals with preexisting illnesses or new-onset disorders difficult and potentially dangerous for both the pregnant individuals and their fetuses. In the meanwhile, we have the moral obligation to support pregnant individuals and their health care practitioners until there is more certainty about the safety of using the different tetracyclines during the 3 stages of pregnancy. As with the administration of any other medication, the potential benefits of using tetracyclines during pregnancy need to be weighed against the risk to the fetus. To improve the current situation, various countries are establishing registries to document possible adverse effects of use of drugs during the different stages of pregnancy. There is, however, a need to promote active, spontaneous reporting of adverse events during pregnancy to ensure rapid generation of evidence regarding the safety of a drug in pregnant individuals. The most frequently dispensed medications during pregnancy are analgesics, antibiotics, and antiemetics. 5 Mansour and colleagues 5 emphasized in their study that additional research is needed on the safety of specific anti-infectives (antibiotics, antifungals, and antivirals) during pregnancy. In summary, pregnant individuals are the last therapeutic orphans and it is time to put everything in place to change that unacceptable situation. Participation in clinical (drug) trials, global registries to document possible adverse effects of exposure to drugs during the different trimesters of pregnancy and during lactation, and an active surveillance system t -Abstract Truncated-
medicine, general & internal